Wainwright Jared D, Alaraj Sami, Wenke Joseph C
University of Texas Medical Branch, 301 University Blvd, Galveston, TX, 77550, USA.
Shriners Children's Texas, 815 Market Street, Galveston, TX, 77550, USA.
J Clin Orthop Trauma. 2024 Jan 3;48:102332. doi: 10.1016/j.jcot.2024.102332. eCollection 2024 Jan.
Despite the fact that preoperative corticosteroid injections within three to six months of surgery increase the risk of postoperative infection, there is a growing trend of using corticosteroid injections intraoperatively as an effort to decrease postoperative pain and opiate use. Our aim with this review was to answer the question "Do intraoperative corticosteroid injections increase the risk of infections in arthroscopic surgery?"
A systematic search of MEDLINE, Cochrane, and PMC databases was conducted adhering to PRISMA 2020 guidelines after registration with PROSPERO (ID: CRD42023459138). We included studies comparing infection rates in patients who received intraoperative corticosteroid injections (IOCSI) to those who received no injection. The MINORS risk of bias tool was used to assess the quality of included studies.
305 individual records were screened and a total of 8 studies met the criteria for inclusion in the study, containing data from over 700,000 patient records. All 7 retrospective studies showed an increase in infection rates and the single small randomized controlled trial had no infections in either the control or intervention group. The combined weighted odds ratio of infection rates in comparable studies was 2.23 95% CI (1.66-3.11).
Current data shows that IOCSIs more than double the risk of postoperative infection during arthroscopic surgery. Surgeons should consider and weigh the impact of infection to the minor clinical benefit corticosteroid injections add over other multimodal injections. We expect similar increases in infection rates in other surgeries where IOCSIs are used due to the inherent immunosuppressive mechanisms of corticosteroids.
尽管术前三到六个月内注射皮质类固醇会增加术后感染风险,但术中使用皮质类固醇注射以降低术后疼痛和减少阿片类药物使用的趋势却在不断增加。我们本次综述的目的是回答“术中皮质类固醇注射会增加关节镜手术感染风险吗?”这一问题。
在向PROSPERO注册(ID:CRD42023459138)后,按照PRISMA 2020指南对MEDLINE、Cochrane和PMC数据库进行了系统检索。我们纳入了比较接受术中皮质类固醇注射(IOCSI)的患者与未接受注射的患者感染率的研究。使用MINORS偏倚风险工具评估纳入研究的质量。
筛选了305条独立记录,共有8项研究符合纳入标准,包含来自70多万份患者记录的数据。所有7项回顾性研究均显示感染率增加,而单项小型随机对照试验的对照组和干预组均未出现感染病例。可比研究中感染率的合并加权比值比为2.23,95%置信区间为(1.66 - 3.11)。
目前的数据表明,在关节镜手术中,术中皮质类固醇注射使术后感染风险增加了一倍多。外科医生应考虑并权衡感染的影响与皮质类固醇注射相对于其他多模式注射所带来的微小临床益处。由于皮质类固醇固有的免疫抑制机制,我们预计在其他使用术中皮质类固醇注射的手术中感染率也会有类似增加。